LUND,
Sweden, Sept. 26, 2022 /PRNewswire/ -- Immunovia
AB (NASDAQ Stockholm: IMMNOV) announced, that the Centers for
Medicare & Medicaid Services (CMS) published a preliminary
payment determination implying a price of $897 for the IMMray PanCan-d test. CMS is a
federal agency within the United States Department of Health and
Human Services that provides health coverage to more than 100
million people in the U.S. CMS sets the basis for payment for lab
tests through the clinical lab free schedule (CLFS).
CMS agreed with the recommendation made by the Clinical
Diagnostic Laboratory Tests (CDLT) Advisory Panel to crosswalk
IMMray PanCan-d rate to code 81503, brand name OVA1, which
currently has a price of $897. After
a period of public comment, CMS will finalize its basis for payment
decision in November.
"Receiving the preliminary payment determination is an
additional milestone on the previously communicated path for
commercialization in the US. We are very pleased that the rate
preliminarily determined by CMS appropriately values our innovative
blood-based test for pancreatic cancer. While this does not
represent a coverage determination to reimburse the IMMray PanCan-d
test, it is an important step in the process of securing
reimbursement for the IMMray PanCan-d test in the early detection
of pancreatic cancer," said Philipp
Mathieu, CEO and President of Immunovia.
For more information, please contact:
Philipp Mathieu
CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
The information in this report is information that Immunovia
AB is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact person set out above, at 08:50 am
CET on September 26, 2022.
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information
see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit https://immunovia.com/
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/centers-for-medicare---medicaid-services-issues-preliminary-payment-rate-determination-for-immunovia,c3636339
The following files are available for download:
https://mb.cision.com/Main/13121/3636339/1630741.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/centers-for-medicare--medicaid-services-issues-preliminary-payment-rate-determination-for-immunovias-immray-pancan-d-test-301632796.html
SOURCE Immunovia AB